Advanced Treatments for Brain Tumors: Secure Procedures Available

Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors

Company creates Younger T Cells for fighting cancer using its NR2F6 technology

Pfizer lung cancer drug misses key survival goal in Phase 3 trial

The company said the safety profile remained consistent with earlier studies and was considered manageable

FDA fast-tracks Roche cancer drug filing after landmark trial shows 50% recurrence reduction

The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized

Automated cell therapy manufacturing attracts US$1.1 Billion across 34 funding rounds

New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones

Lonza, Antharis partner to develop next-generation dual-payload ADCs for GI cancers

Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise

Alembic Pharma receives USFDA tentative approval for generic Larotrectinib capsules

Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.

AmMax Bio licenses Lonza’s ADC tech to advance AML candidate AMB-104

The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027

Johnson & Johnson to acquire Firefly Bio in $1 billion oncology push

The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities

AbbVie showcases broad blood cancer pipeline at EHA 2026 with 21 presentations

The company will present 21 oral and poster presentations spanning investigational and approved therapies